The IMP (IGFII mRNA-binding protein) family comprises a group of three RNA-binding proteins involved in the regulation of cytoplasmic mRNA-fate. Recent studies identified IMP proteins as oncofetal factors in various neoplasias, but knowledge of a potential role in ovarian carcinomas is still lacking. The immunohistochemical analysis of 107 ovarian carcinomas, 30 serous borderline tumors of the ovary and five normal ovaries revealed de novo synthesis of IMP1 in 69% of ovarian carcinomas. Elevated IMP1 expression was observed preferentially in high-grade and high-stage cases and was a significant prognostic indicator for reduced recurrence-free and overall survival. Phenotypic studies in ovarian carcinoma-derived ES-2 cells demonstrated that IMP1 knockdown affects proliferation and cell survival. Reduced proliferation was associated with decreased c-myc mRNA half-life, suggesting IMP1 as an oncogenic factor that is involved in promoting elevated proliferation by stabilizing the c-myc mRNA in ovarian carcinoma cells.
The IMP (IGFII mRNA-binding protein) family comprises three RNA-binding proteins (IMP1-3) that determine the cytoplasmic fate of specific mRNAs. Members of the protein family direct mRNA localization, translation or mRNA stability of their target transcripts (Yisraeli, 2005) . All IMP proteins are primarily expressed during embryogenesis and mid-gestation in mouse with almost no detectable expression in the postnatal phase (Mueller-Pillasch et al., 1999; Nielsen et al., 1999; Hansen et al., 2004) . Deletion of IMP1 expression in mice results in dwarfism, impaired development of the gut and increased perinatal lethality (Hansen et al., 2004) . In Xenopus, the ortholog Vg1-RBP is essential for the control of neuronal crest cell migration (Yaniv et al., 2003) . In primary mammalian neurons as well as neuroblastoma cells, IMP1, also termed ZBP1 (zipcode-binding protein 1) regulates localized translation of the b-actin mRNA in growth cones and neurites supporting an important role of IMP proteins for guiding normal development and directing cell migration (Huttelmaier et al., 2005) .
Although additional target mRNAs of IMP1 are expected, solid evidence indicates that IMP1 is essential for the regulation of c-myc, bTrCP1 and CD44 mRNA turnover, but also facilitates translational control of the IGF-II and b-actin mRNAs (Nielsen et al., 1999; Lemm and Ross, 2002; Huttelmaier et al., 2005; Noubissi et al., 2006; Vikesaa et al., 2006) . While by the regulation of IGF-II and c-myc expression IMP1 is expected to affect cell proliferation, growth and survival, the regulation of CD44 or b-actin expression via IMP1 is suggested to modulate cell adhesion, invadopodia formation and actin dynamics.
A role of IMP proteins in tumor progression was suggested based on the aberrant expression of IMP proteins in various neoplasias (Yaniv and Yisraeli, 2002; Yisraeli, 2005) . In human cancers, de novo synthesis of IMPs was identified in approximately 80% of colorectal carcinomas, 70% of bone and soft tissue sarcomas, 60% of breast carcinomas and 50% of non-small cell lung carcinomas (Ioannidis et al., 2001 (Ioannidis et al., , 2003 (Ioannidis et al., , 2004 Ross et al., 2001) . A pivotal role of IMP1 in colorectal cancer progression was emphasized by recent studies demonstrating that IMP1 mediates stabilization of the bTrCP1 mRNA in response to b-catenin signaling (Noubissi et al., 2006) . In primary ovarian carcinoma, only one study reported an overexpression of IMPs based on semiquantitative reverse transcription-PCR (RT-PCR) analyses in carcinoma vs adenoma, but the functional role of IMP1 in ovarian carcinoma-derived cells was not evaluated (Gu et al., 2004) .
The expression of IMP proteins in ovarian carcinomas, serous borderline tumors (SBOTs) of the ovary and normal ovaries was analysed by immunohistochemistry using an anti-IMP1 serum with minimal cross-reactivity to the members of the IMP-family (Supplementary Figure S1 ). Normal ovarian surface epithelium as well as stroma showed no immunoreactivity with IMP1 ( Figure 1a) . Likewise, in SBOTs no IMP1 expression was identified (Figure 1b) . Intense de novo synthesis was observed in ovarian carcinomas (73/106 cases; 69%) and 77% of serous carcinomas showing high staining intensity in the cytoplasm of tumor cells without any stromal background signal (Figures 1c and d) .
Since IMP1 was upregulated in the majority of analysed ovarian carcinomas, the observed expression pattern was correlated with traditional clinicopathological parameters and survival. IMP1 expression was related to a high International Federation of Gynecology and Obstetrics (FIGO) stage (P ¼ 0.03), high histological grade (P ¼ 0.04), the presence of more than 500 ml ascites (P ¼ 0.001) and residual tumor (P ¼ 0.006; Supplementary Table 1) . A univariate Kaplan-Meier survival analysis revealed that expression of IMP1 in ovarian carcinomas was associated with significant shorter recurrence-free and overall survival (Figure 2) . Moreover, using univariate cyclooxygenase (COX) regression model, the hazard ratio (HR) for recurrence was estimated with 1.7, P ¼ 0.04 (Supplementary  Table 2 ) and for tumor-related death with 2.1, P ¼ 0.03 (Supplementary Table 3 ). However, residual tumor was the most predictive parameter for recurrence (HR 12.0) and tumor-related death (HR 6.5) in univariate analysis. When introducing these factors in a multivariate analysis using the COX hazard regression model, only residual tumor, adequate chemotherapy and FIGO stage remained significant for survival. Notably, IMP1 expression was elevated in most carcinomas and expression was increased in high-grade and high-stage ovarian carcinomas supporting a role of IMP1 in ovarian carcinoma progression.
To evaluate the role of IMP1 in ovarian carcinomas, phenotypic effects of aberrant IMP1 expression were analysed by small interfering RNA (siRNA)-mediated Immunostaining was performed on paraffin-embedded tissue sections, as described previously (Kobel et al., 2006) , using a IMP1 (ZBP1)-directed antibody (Farina et al., 2003; Huttelmaier et al., 2005) . Two slides per sample were immunostained together in two runs before the semiquantitative evaluation of the immunoreactivity by a pathologist (MK) blinded to the clinical data. Staining intensity of tumor cells as well as percentage of positive tumor cells was recorded. A positive case was declared as positive when at least 5% of tumor cells were clearly stained. To examine reproducibility of IMP1 immunohistochemistry evaluation, the set was reevaluated by a secondblinded pathologist (KZ). In divergent cases (5%), agreement about sample classification was achieved at a multiheaded microscope. IMP, IGFII mRNA-binding protein; ZBP1, zipcode-binding protein 1. IMP1 function in ovarian carcinoma M Köbel et al knockdown in ovarian cancer derived-cell lines. Previous studies revealed that IMP1 knockdown in mammary adenocarcinoma-derived MCF-7 cells resulted in reduced proliferation correlating with decreased steady state levels of c-MYC (Ioannidis et al., 2005) . In contrast, the knockdown of IMP1 caused increased proliferation correlating with elevated IGF-II protein levels in K562 leukemia cells (Liao et al., 2004) . In agreement with studies performed in MCF-7 cells, IMP1 knockdown in ovarian carcinoma-derived ES-2 induced decreased proliferation starting 72 h after the transfection of siRNAs. In contrast, OVCAR-3 cells remained basically unaffected (Figures 3a and b) . Since previous studies correlated reduced proliferation observed upon IMP1 knockdown with a destabilization of the c-myc mRNA, the relative expression of IMP1 and c-myc was compared between both cell lines. Semiquantitative western blotting and cross-normalized quantitative RT-PCR analyses revealed a significantly higher expression of IMP1 and c-myc in ES-2 cells (Figures 3c and d) . These differences in expression levels correlated with an increased proliferation efficiency of ES-2 compared to OVCAR-3 cells (Supplementary Figure S2) . Therefore, we hypothesized that the stabilization of the c-myc mRNA by IMP1 was involved in directing elevated proliferation rates of ES-2 and the susceptibility of ES-2 Figure 3 IMP1 regulates proliferation in ovarian carcinoma-derived cell lines. (a) Cell viability was determined in ES-2 or OVCAR-3 cells at indicated time points after IMP1-directed siRNA transfection and normalization to cell viability in a population transfected with control siRNAs. The siRNAs used (one siRNA directed against IMP1 and one control siRNA) were as described previously (Huttelmaier et al., 2005) . (b) ES-2 cell numbers were determined at indicated time points after siRNA transfection and normalization to cell numbers at 24 h post-transfection (100%). ) were transfected with siRNAs using Lipofectamine2000 for 6 h before plating defined cell numbers. At various time points post-transfection cell viability was determined, according to the manufacturer's instruction. In (a), relative cell viability was determined between ES-2 or OVCAR-3 cells transfected with IMP1 or control siRNAs, respectively. In (b), ES-2 cell numbers were determined post-transfection of indicated siRNAs and normalization to cell numbers 24 h post-transfection, set to 100%. The specific knockdown of IMP1 was determined by western blotting of OVCAR-3 and ES-2 cell lysates 72 h post-transfection with anti-vinculin (Sigma, Mu¨nchen, Germany), anti-tubulin (Sigma) and anti-IMP1 (ZBP1) (Farina et al., 2003) , as described previously (Huttelmaier et al., 2005) . Relative expression levels of indicated genes were determined by quantitative RT-PCR (d). Total RNA (2 mg) was used for reverse transcription with random primers and MMLV-RT (Promega). Quantitative PCR was performed based on SYBRgreen technology using a Taq-Master mix (Promega) in a MX3000p cycler (Stratagene, Amsterdam, Netherlands). For all primer pairs (Supplementary Table 4 ) an annealing temperature of 601C was used. Relative changes of mRNA amounts were calculated based on the DC t -method by cross-normalization to cyclophilinA, vinculin and a-tubulin mRNA, as described by Livak and Schmittgen (2001) . IMP, IGFII mRNA-binding protein; MMLV, Moloney murine leukemia virus; RT-PCR, reverse transcription-PCR; siRNA, small interfering RNA; ZBP1, zipcode-binding protein 1.
cell proliferation to IMP1 knockdown, as recently demonstrated for MCF-7 cells (Ioannidis et al., 2005) . This assumption was supported by reduced steady state c-myc mRNA levels and elevated c-myc mRNA decay (t 1/2 (IMP1 knockdown) E20 min; t 1/2 (control) E40 min) observed upon IMP1 knockdown (Figures 4a  and b; Supplementary Figure S5 ). The destabilization of the c-myc mRNA was associated with decreased c-Myc protein levels at steady state in cells treated with IMP1-directed siRNAs (Figures 4c and d ; Supplementary Figure S5) . Moreover, the knockdown of IMP1 led to reduced luciferase activity expressed from a reporter construct comprising the c-myc CRD-element (coding region determinant) in frame to the luciferase coding sequence, whereas a control reporter lacking the CRD region remained unaffected by the knockdown of IMP1 (Supplementary Figure S3) . Hence, IMP1 was confirmed to be essential for controlling c-myc mRNA turnover via the CRD-element located in the coding region of the c-myc mRNA, as suggested previously (Lemm and Ross, 2002; Sparanese and Lee, 2007) .
In conclusion, the study reported here provides new in vivo and in vitro findings, suggesting a role of IMP1 in ovarian carcinomas. In agreement with a recent study suggesting aberrant IMP expression in ovarian carcinomas on the basis of semiquantitative RT-PCR analyses (Gu et al., 2004) , the majority of here analysed ovarian carcinoma samples (69% of cases) expressed IMP1 without any stromal background. Normal surface epithelium of the ovary was negative for IMP1 supporting the finding that IMP1 is almost exclusively expressed during embryogenesis, (Mueller-Pillasch et al., 1999; Nielsen et al., 1999; Hansen et al., 2004) . Notably, IMP1 expression was not detected in borderline tumors of the ovary providing further evidence that SBOTs are not precursors of high-grade serous carcinomas (Shih Ie and Kurman, 2004) .
IMP1 expression was elevated in high-stage and high-grade tumors (76% of analysed FIGOIII/IV stage tumors, 68 cases, 73% of high-grade tumors, 77 cases; Supplementary Table 1 ), suggesting that IMP1 expression is increased with the 'grade of malignancy', as previously reported for other neoplasias (Yaniv and Yisraeli, 2002) . It was therefore not surprising to identify IMP1 expression to correlate with a reduced recurrence-free as well as overall survival in univariate analysis. However, when introduced to multivariate analyses, it failed to confer prognostic information indicating that IMP1 might only serve as an additional rather than a single prognostic marker for clinical practice, at least from the data presented here. Knockdown of IMP1 in ovarian carcinoma-derived ES-2 cell expressing IMP1 at high levels compared to OVCAR-3 cells resulted in reduced proliferation correlating with decreased c-myc mRNA and protein levels at steady state and elevated decay of the c-myc mRNA. Moreover, luciferase activity expressed from a reporter transcript comprising the c-myc CRD-element in frame to the luciferase coding sequence was reduced upon IMP1 knockdown. A similar effect was observed in other studies with MCF-7 cells in which steadystate levels of c-myc mRNA and protein as well as proliferation rates were reduced upon IMP1 knockdown (Ioannidis et al., 2005) . Hence, the analyses presented here provides further evidence that the knockdown of IMP1 can influence proliferation rates of tumor cells by inducing elevated decay of the c-myc mRNA. Apparently, this effect is increased in tumor cells expressing elevated levels of c-myc. Notably, other studies demonstrated that increased c-myc expression is observed in up to 66% ovarian carcinomas, while only 35% of tumors show c-myc gene amplification (Chen et al., 2005; Dimova et al., 2006) . Thus, beside c-myc gains, additional mechanisms must exist to explain elevated c-myc expression in neoplasias. Increased c-myc expression is likely to promote proliferation in tumor cells, a s demonstrated by the observation that c-myc knockdown led to a significant reduction of proliferation rates in ES-2 cells (Supplementary Figure S4) . Therefore, our findings suggest that the de novo synthesis of IMP1 observed in a large fraction of ovarian carcinomas can serve as an additional prognostic marker. In ovarian carcinoma cells, IMP1 apparently contributes to sustaining elevated c-myc expression by increasing the c-myc mRNA half-life. This role is promoted in cells with elevated c-myc expression leading to increased proliferation rates.
